Sophie Vériter, Ph.D. in Biomedical and Pharmaceutical Sciences joins 2 Bridge as R&D Director. At 2 Bridge, she will be involved in CMC projects and scientific development activities, and support the development of innovative therapies, mainly in the field of Cell and Gene Therapy.
Sophie is a scientist with a passion for innovative therapies to improve health and quality of life.
She has over 10 years of professional experience in the field of cell therapy in regenerative medicine. She has been involved in the creation of a Belgian biotech, Novadip Biosciences, from the academic bench to cell therapy products currently being tested in phase I/II clinical trials. Sophie led the discovery and preclinical development of innovative cell therapy products and biologics as well as early R&D activities on extracellular vesicles. More recently, she was part of the CMC and non-clinical team of a clinical-stage subsidiary of Fresenius Medical Care, Unicyte AG, focusing on the development of cell therapies and extracellular vesicles.
Flexible, dynamic, and solutions-oriented, Sophie enjoys working in a fast-paced environment where adaptability and continuous improvements are needed.